By downregulating key efflux transporters like P-glycoprotein (ABCB1) and BCRP (ABCG2) and modifying chromatin accessibility, HDACis may enhance intracellular drug retention and re-sensitize resistant breast cancer cells to conventional chemotherapeutics [18]. The gene discussed is ABCG2; the disease is breast carcinoma.